GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Navco Pharmaceuticals Inc (TSXV:NAV) » Definitions » YoY EBITDA Growth

Navco Pharmaceuticals (TSXV:NAV) YoY EBITDA Growth : 200.00% (As of Mar. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Navco Pharmaceuticals YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Navco Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Mar. 2023 was 200.00%.

Navco Pharmaceuticals's EBITDA per Share for the three months ended in Mar. 2023 was C$0.00.


Navco Pharmaceuticals YoY EBITDA Growth Historical Data

The historical data trend for Navco Pharmaceuticals's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Navco Pharmaceuticals YoY EBITDA Growth Chart

Navco Pharmaceuticals Annual Data
Trend Jun18 Jun19 Jun20 Jun21
YoY EBITDA Growth
- - 82.46 -55.00

Navco Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 57.14 -58.33 66.67 70.00 200.00

Navco Pharmaceuticals YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Navco Pharmaceuticals's YoY EBITDA Growth for the fiscal year that ended in Jun. 2021 is calculated as:

YoY EBITDA Growth (A: Jun. 2021 )
=(EBITDA per Share (A: Jun. 2021 )-EBITDA per Share (A: Jun. 2020 ))/ | EBITDA per Share (A: Jun. 2020 ) |
=(-0.031--0.02)/ | -0.02 |
=-55.00 %

Navco Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Mar. 2023 is calculated as:

YoY EBITDA Growth (Q: Mar. 2023 )
=(EBITDA per Share (Q: Mar. 2023 )-EBITDA per Share (Q: Mar. 2022 )) / | EBITDA per Share (Q: Mar. 2022 )) |
=(0.003--0.003)/ | -0.003 |
=200.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Navco Pharmaceuticals YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Navco Pharmaceuticals's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Navco Pharmaceuticals (TSXV:NAV) Business Description

Traded in Other Exchanges
N/A
Address
1055 West Georgia Street, Suite 1500, Vancouver, BC, CAN, V6E 4N7
Website
Navco Pharmaceuticals Inc uses of nanotechnology to develop and commercialize novel products to protect against viruses, bacteria, and infectious diseases. The company's pipeline of applications is tailored to defend against pathogens utilizing new methods of action to capitalize on unmet product needs using natural & known compounds, nanoparticles, and no chemicals with a high degree of efficacy. Its target markets include human health & personal skin care, household & institutional products, and veterinary health.

Navco Pharmaceuticals (TSXV:NAV) Headlines